Results 61 to 70 of about 104,915 (286)

Two-year follow-up of macaques developing intermittent control of the human immunodeficiency virus homolog simian immunodeficiency virus SIVmac251 in the chronic phase of infection [PDF]

, 2015
Off-therapy control of viremia by HIV-infected individuals has been associated with two likely players: a restricted viral reservoir and an efficient cell-mediated immune response.
Arts, Eric, Biffoni, Mauro, Chung, Hye Kyung, Farrell, Nicholas, Labranche, Celia, Lewis, Mark G., Montefiori, David, Nickel, Gabrielle, Pal, Ranajit, PALAMARA, ANNA TERESA, Robert Guroff, Marjorie, Sacha, Jonah B., Savarino, Andrea, Shytaj, Iart Luca, Vargas Inchaustegui, Diego   +14 more
core   +2 more sources

Respiratory Organ‐on‐a‐Chip for Disease Modeling: From Architecture to Functional Integration

Advanced Healthcare Materials, EarlyView.
Respiratory organ‐on‐a‐chip (ROC) models capture key mechanical and cellular cues of the human respiratory system, enabling quantitative dissection of disease mechanisms. This review links ROC architectures to disease modeling, functional integration, and commercialization, and proposes a decision framework that aligns model complexity with mechanistic
Jinzhuo Hu, Yongjie Tang, Sidi Liu, Tao Xu, Qian Liu   +4 more
wiley   +1 more source

Halofuginone is a Molecular Glue Degrader of Integrin β4

Advanced Science, EarlyView.
Integrin β4 overexpression is linked to aggressive tumors and poor prognosis, but targeted therapies are lacking. We identified halofuginone (HF) as a molecular glue degrader that promotes integrin β4 degradation via the CRL4BWDR18 E3 ligase. HF suppresses tumor progression in vitro and in vivo, offering a new strategy for targeting oncogenic ...
Wei Gong, Di Yang, Junrui Tian, Yufei Chai, Tiantian Yu, Qingnan Wu, Yan Wang, Weimin Zhang, Qimin Zhan   +8 more
wiley   +1 more source

Characteristics and survival of patients with advanced cancer and p53 mutations. [PDF]

, 2014
P53 mutations are associated with invasive tumors in mouse models. We assessed the p53mutations and survival in patients with advanced cancer treated in the Phase I Program. Of 691 tested patients, 273 (39.5%) had p53 mutations.
Aldape, Kenneth, Fu, Siqing, Hess, Kenneth R, Hong, David S, Janku, Filip, Kurzrock, Razelle, Naing, Aung, Palmer, Gary A, Said, Rabih, Thomas, Christoforos, Tsimberidou, Apostolia M, Wheler, Jennifer J, Ye, Yang   +12 more
core   +9 more sources

New drugs in prostate cancer

Prostate International, 2016
The standard primary treatment for advanced prostate cancer has been hormonal therapy since the 1940s. However, prostate cancer inevitably progresses to castration-resistant prostate cancer (CRPC) after a median duration of 18 months of androgen ...
Sangjun Yoo, Se Young Choi, Dalsan You, Choung-Soo Kim   +3 more
doaj   +1 more source

A Research Documentation On Men's Sexual Health Disclosed [PDF]

, 2010
When VigRX Plus was surveyed by Vedic Life-Sciences in proved to be the best pill treatment for sexual health.

core  

Mavrilimumab, a fully human granulocyte-macrophage colony-stimulating factor receptor α monoclonal antibody: long-term safety and efficacy in patients with rheumatoid arthritis [PDF]

, 2018
Objective: Mavrilimumab, a human monoclonal antibody, targets granulocyte-macrophage colony-stimulating factor receptor alpha. We report mavrilimumab long-term safety and efficacy in rheumatoid arthritis patients in two phase IIb studies (1071, 1107 ...
Achuthan, Akagawa, Aletaha, Aletaha, Antoniu, Avci, Berghen, Borg, Borie, Brown, Buch, Burmester, Burmester, Calisto, Cella, Chen, Cook, Cornish, Cottin, Crotti, Dawson, Felson, Fleetwood, Fries, Greven, Guo, Hamilton, Jaguin, Kelly, Khan, Lazaro, Listing, Minter, Prevoo, Shaw, Shibata, Singh, Tsuchiya, Van der Heijde, Van Gestel, Van Onna, Ware, Weinblatt, Yoshida, Zhan   +44 more
core   +1 more source

Cognitive Trajectories from Preclinical Alzheimer's Disease to Dementia

Advanced Science, EarlyView.
A continuous, multi‐domain characterization of cognitive decline across the Alzheimer's disease spectrum identifies when individual cognitive measures become abnormal. Episodic memory declines first, followed by executive function, language, processing speed, and visuospatial abilities, supporting improved clinical interpretation and optimized endpoint
Fredrik Öhman, Lars Lau Raket, Michael Schöll, for the Alzheimer's Disease Neuroimaging Initiative†   +3 more
wiley   +1 more source

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. [PDF]

, 2016
Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II ...
Falchook, Gerald S., Fanale, Michelle A., Fu, Siqing, Garrido-Laguna, Ignacio, Hong, David S., Janku, Filip, Kaseb, Ahmed O., Kurzrock, Razelle, Meric-Bernstam, Funda, Naing, Aung, Park, Haeseong, Patel, Shreyaskumar, Piha-Paul, Sarina A., Subbiah, Vivek, Tsimberidou, Apostolia M., Velez-Bravo, Vivianne M M., Wheler, Jennifer J., Zinner, Ralph G.   +17 more
core   +2 more sources

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source